Monitoring And Follow-Up Protocols For Patients With Essential Iris Atrophy
Published on: February 25, 2026
Monitoring and Follow-Up Protocols for Patients with Essential Iris Atrophy featured image
  • Article reviewer photo

    Afshah Kabir

    MSc Physician Associate Studies

  • Article reviewer photo

    Paramvir Singh

    RPh; Master of Pharmacy (MPharm), Pt BD Sharma University of Health Sciences, India

Introduction

Have you ever seen someone and their pupils look different, maybe off-centre or oddly shaped? Well, in some rare cases, it might be more than a cosmetic change; it could be essential iris atrophy. A rare condition that affects the coloured part of the eye and can even lead to glaucoma if not managed. This article provides an overview of essential iris atrophy, monitoring, follow-up protocol, and recommendations for referral.

Understanding essential iris atrophy

Essential iris atrophy (EIA) is a very rare, progressive disorder of the eye characterised by pupil displacement and/or a distorted area of degeneration of the iris (atrophy), and/or holes in the iris. It is usually unilateral and progressive and subsequently leads to closure of the drainage canal, causing glaucoma.1

This condition is one of the clinical variants of Iridocorneal endothelial syndrome (ICE-S), a group of rare eye conditions characterised by increased proliferation and migration of corneal tissue to the iris and iridocorneal angle.2 Other variants include Chandler Syndrome and Cogan-Reese Syndrome, all of which, if left untreated, can lead to blindness.3

ICE-S was first reported by Eagle and Yanoff in 1979, and these groups of eye defects usually affect one eye (unilateral) and occur most frequently in young and middle-aged women with no family history and usually in the caucasian population.4 However, studies have highlighted bilateral occurrence and cases of EIA in males.5

Biomicroscopy of EIA. Credit4

Essential Iris Atrophy showing holes in the pupil. Credit8

Aetiology of essential iris atrophy

The cause of this disease is unknown, although some hypotheses have been developed to explain it. One theory suggests that this condition can be caused by a herpes simplex virus infection, which integrates viral genetic material into the human genome, changes the activity and morphology of endothelial cells, and causes them to proliferate abnormally.4

Another such theory, the membrane theory, assumes that ICE-S are mainly of corneal origin and then further degeneration and proliferation of the endothelial cells, which then impacts the Iris.5 While this disease is rare, several studies have identified its prevalence, especially according to race or ethnicity.

Among all the ICE syndromes, EIA has the highest incidence of 66.67% among the Indian population.

Symptoms of essential iris atrophy

Essential Iris Atrophy is a progressive disease, and symptoms develop gradually over time. Changes in the shape and placement of the pupils typically occur before any vision change.1 Other symptoms include thinning of the iris and formation of holes, as well as changes in eye drainage and pressure due to blockage of the drainage angle.

Fluid may accumulate in the eye, increase intraocular pressure, and cause secondary glaucoma. Occasionally, patients develop eye and head pain as a result of high intraocular pressure, changes in eye colour such as the affected eye becoming lighter or darker than the other eye, and the edges of the iris turning outward.6 These symptoms, if not properly managed, can lead to vision loss.

Initial assessment and diagnosis of essential iris atrophy

To make sure that ocular changes are a result of EIA and ensure a differential diagnosis, the following assessments are performed: 

  • Slit-lamp biomicroscopy (to assess iris changes)
  • Gonioscopy (to evaluate the drainage angle)
  • Intraocular pressure (IOP) measurement
  • Corneal endothelial cell count using specular microscopy
  • Optic nerve assessment and visual field testing

Management of essential iris atrophy

While there is no effective treatment to halt this disease, management typically involves temporary measures targeted at controlling intraocular pressure and corneal clarity.6 Due to the younger age of people presenting with this disease and the fact that they usually have preexisting glaucoma, treatment requires both medical treatment and surgical procedures to manage glaucoma.6

Treatment of EIA usually involves topical agents like drops to control glaucoma and corneal oedema.1 Mild cases of corneal swelling are usually managed with soft contact lenses and hypertonic saline, while advanced cases may require some sort of corneal transplant, although a high failure rate has been reported with this procedure.1 The hallmark of medical therapy for EIA is the reduction of intraocular pressure, which can be done using drugs such as beta blockers, alpha-2 agonists, carbonic anhydrase inhibitors and prostaglandin analogues. 

However, a large number of EIA patients require surgery to reduce intraocular pressure.1 Although some literature suggests that EIA can be caused by viruses such as Epstein-Barr virus and varicella zoster virus, there is, however, no evidence that treatment with antivirals alters disease progression.6 Currently, there is a procedure for iris reconstruction with or without an intraocular prosthesis, both for cosmetic reasons and visual disturbance issues.7

Why regular monitoring and follow-up are crucial

Essential iris atrophy is a progressive condition that can lead to complications such as secondary glaucoma and corneal oedema, both of which are vision-threatening conditions. 

Therefore, early monitoring is essential to detect these complications early and manage them to prevent worsening and subsequent vision loss.3

Monitoring and follow-up protocols

The following monitoring and follow-up protocols are recommended for EIA patients to manage symptoms and detect complications early:

Regular follow-ups

If diagnosed with EIA, patients are booked for subsequent appointments to ensure conditions are adequately monitored and complications are handled promptly. How often an appointment is set will depend on the presence or absence of glaucoma. If glaucoma is absent, patients can expect to visit the doctor every 3 months.

However, if present, patients can visit every 2-3 months.4 At each visit, the doctor will check for iris thinning exacerbation, an increase in eye pressure, or if the cornea is getting cloudy. Also, seeing halos, feeling pain, or noticing vision changes are assessed, and patients are reminded to stick to any prescribed treatments.

Tests during follow-ups

During each visit, the patient undergoes various eye examinations, including monitoring of eye pressure and glaucoma via regular intraocular pressure measurements, examination of the eye’s drainage system using gonioscopy, assessment of peripheral vision, and evaluation of the optic nerve. In cases where corneal cloudiness obscures visibility, an ultrasound, resembling a miniature eye scan, may be employed for clearer imaging.3

The cornea’s health is assessed by examining for swelling, with its thickness and cell condition evaluated using a microscope. Detailed scans, conducted with technologies such as optical coherence tomography (OCT), are used to monitor the optic nerve and deeper layers of the eyes, ensuring that subtle changes are detected.7 

Medication monitoring

EIA patients are usually started on topical medications to reduce intraocular pressure; mostly, these drops (beta blockers, carbonic anhydrase) lose efficacy on long-term usage, hence monitoring is essential to identify when drops are no longer effective to adopt better ways of managing intraocular pressure.3

If drops fail, a surgical procedure such as trabeculotomy is adopted to drain fluids from the eye; also, in the advanced stage of cornea oedema, cornea transplant surgery can be done. After surgery, a doctor's appointment is booked every 1-3 months to ensure efficiency and safety.3

Long-term management and referrals

Management of EIA is a team effort; eye doctors usually work closely with specialists in glaucoma and cornea to tailor your care, especially if surgery is needed. Patients are educated on their conditions, how to use their drops and how to monitor and report any symptoms, such as pain and vision disturbances. Also, in cases where glaucoma worsens despite the use of drops, referral is made to a specialist for advanced tests and procedures. Effective monitoring of EIA requires proactive measures, keeping to appointments, adhering to medications and reporting symptoms.

Summary 

Essential Iris Atrophy (EIA) is a rare, progressive eye condition that can lead to glaucoma or corneal issues and eventually, blindness if not properly managed. Regular monitoring, starting with a thorough initial exam and followed by check-ups every 2-3 months, using tests such as gonioscopy and OCT to track eye pressure, iris changes, and corneal health, is essential. Medications like eye drops are the first line of defence, but surgery may be needed if they fail. Early detection and consistent follow-ups, guided by a team of eye specialists, are crucial to prevent blindness and maintain quality of life. By staying on top of these protocols, patients can catch problems early and keep their eyes as healthy as possible.

References

  1. Essential Iris Atrophy - Symptoms, Causes, Treatment. NORD [Internet]. [cited 2025 Oct 10]. Available from: https://rarediseases.org/rare-diseases/essential-iris-atrophy/. 
  2. Atlas Entry: Essential iris atrophy, iridocorneal endothelial (ICE) syndrome. EyeRounds [Internet]. [cited 2025 Oct 10]. Available from: https://eyerounds.org/atlas/pages/essential-iris-atrophy/#gsc.tab=0. 
  3. Das S, Tripathy K. Iridocorneal Endothelial Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK594227/. 
  4. Beganovic AP, Vodencarevic AN, Halilbasic M, Medjedovic A. Iridocorneal Endothelial Syndrome: Case Report of Essential Progressive Iris Atrophy. Med Arch [Internet]. 2022; 76(3):224–8 [cited 2025 Oct 13]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478812/. 
  5. Malhotra C, Seth NG, Pandav SS, Jain AK, Kaushik S, Gupta A, et al. Iridocorneal endothelial syndrome: Evaluation of patient demographics and endothelial morphology by in vivo confocal microscopy in an Indian cohort. Indian J Ophthalmol [Internet]. 2019;67(5):604–610. [cited 2025 Oct 13] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498939/. 
  6. Walkden A, Au L. Iridocorneal endothelial syndrome: clinical perspectives. Clin Ophthalmol [Internet]. 2018; 12:657–64. [cited 2025 Oct 13] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898599/. 
  7. Sacchetti M, Mantelli F, Marenco M, Macchi I, Ambrosio O, Rama P. Diagnosis and Management of Iridocorneal Endothelial Syndrome. BioMed Research International [Internet]. 2015; 2015:1–9. [cited 2025 Oct 15] Available from: http://www.hindawi.com/journals/bmri/2015/763093/. 
  8. Essential Iris Atrophy. EyeWiki [Internet]. [cited 2025 Oct 17]. Available from: https://eyewiki.org/File:Essential_Iris_Atrophy!.jpg.
Share

Augusta Onyinyechi Opara

arrow-right